

Physiological based Models for the Analysis of Liver Function

Dr Matthias König

LiSyM Systems Medicine of the Liver

Humboldt University Berlin, Institute for Theoretical Biology

livermetabolism.com

@konigmatt



Physiological compartment models

- Absorption, Distribution, Metabolism, Elimination (ADME)




FIGURE 2-5. A drug is simultaneously absorbed into the body and eliminated from it, by excretion and metabolism. The processes of absorption, excretion, and metabolism are indicated with arrows and the compartments with ovals. The compartments represent different locations and different chemical species (color = metabolite). Metabolite elimination may occur by further metabolism or excretion.

$$\text{Dose} = \frac{\text{Amount at}}{\text{Absorption Site}} + \frac{\text{Amount}}{\text{in Body}} + \frac{\text{Amount}}{\text{Excreted}} + \frac{\text{Amount}}{\text{Metabolized}}$$
$$\text{Rate of Change of Drug in Body} = \frac{\text{Rate of}}{\text{Absorption}} - \left[\frac{\text{Rate of}}{\text{Excretion}} + \frac{\text{Rate of}}{\text{Metabolism}} \right]$$







FIGURE 2-6. Time course of drug and metabolite in each of the compartments shown in Fig. 2-5. The amount in each compartment is expressed as a percentage of the dose administered. In this example, all the dose is absorbed. At any time, the sum of the molar amounts in the five compartments equals the dose.



Physiological-based pharmacokinetics models (PBPK)

- pharmacokinetics: determines fate of substances administered to organism
- combines information on the drug with knowledge on the physiology and biology at organism level
- human/animal physiology in the computer
- **Tissues are linked by arterial and venous blood compartments** characterized by associated blood flow rates, tissue-partition coefficient , and permeability
- Specific models for certain drugs & substances
- Result: Time dependent concentrations of substances/drugs in organs, blood & urine
- High pharmacological relevance since it enables the estimation of drug exposure not only in plasma but also at the site of action



Example: Glucose-Insulin system





Fig. 2. Scheme of the glucose-insulin control system which puts in relation the measured plasma concentrations, i.e., glucose G , and insulin I , to glucose fluxes, i.e., rate of appearance Ru , production EGP , utilization U , renal extraction E , and insulin fluxes, i.e., secretion S , and degradation D .



Pharmacokinetic Parameters




FIGURE 2-1. Drug concentration–time curve following a single oral dose showing the maximum systemic exposure (C_{\max}) and the time of its occurrence (t_{\max}). The concentration could represent drug in whole blood, plasma, or serum.





FIGURE 3-4. A. Plasma concentration of midazolam with time in an individual after an 8.35-mg i.v. bolus dose of midazolam hydrochloride (7.5 mg of the base) in a healthy adult. B. The data in A are redisplayed as a semilogarithmic plot. Note the short distribution phase. (From: Pentikäinen PJ, Välijoki L, Himberg JJ, Crevoisier C. Pharmacokinetics of midazolam following i.v. and oral administration in patients with chronic liver disease and in healthy subjects. *J Clin Pharmacol* 1989;29: 272–277.)

- C_{\max} : Maximal concentration
- T_{\max} : time of maximal concentration
- **AUC** : area under the curve
- k_{el} : elimination rate fitting linear part of terminal phase (log)
- $t_{1/2}$: half-life ($= \ln 2/k_{el}$) time for concentration to fall to half
- **Vd**: volume of distribution ($= CL/k$), dilution space
- **CL**: clearance ($= \text{Dose}/\text{AUC}$, $= \text{Dose}/C(0)_{\text{extrapolated}}$)

Building blocks of a PBPK model



Kuepfer2016

Differential equations

▪ Compartments

- organs

▪ State variables:

- drug & metabolite amounts

▪ ODEs & rules

- Blood flows, Transport, Disposition

- Metabolism, Elimination

- Absorption

▪ Parameters

- Tissue partition coefficients

- Protein binding

- Kinetic parameter (transport & elimination)

- Blood flows, organ volumes, ...

PBPK Applications

Cross-Species Extrapolation


PBPK models can be used to facilitate the extrapolation of knowledge generated in various preclinical species to humans

In silico drug trials



Special Populations


By including the appropriate physiological information, PBPK models can be used to make predictions in special populations



Drug Drug Interactions (DDI)

Thanks of the explicit inclusion of enzymatic processes, the combination of two or more models allow the prediction of interaction between drugs

Individual Dosing



Advanced Applications

PBPK models can also be integrated in more complex models such as multiscale modelling or statistical modelling, using methods such as Bayesian approaches

Figure 3 Schematic representation of the most common applications of PBPK modeling.

Large inter-individual variability




FIGURE 1-8. There is considerable interindividual pharmacodynamic variability in response to the oral antiocoagulant warfarin as demonstrated by the substantial spread in the unbound concentration of the active S-isomer associated with a similar degree of anticoagulation in a group of 97 patients on maintenance therapy. (From: Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms of warfarin maintenance dose and metabolic clearance. *Clin Pharmacol Ther* 2002;72:702–710.)




FIGURE 1-7. Although the average plasma concentration of phenytoin on chronic dosing tends to increase with the dosing rate, there is large variation in the individual values. (From: Lund, L. Effects of phenytoin in patients with epilepsy in relation to its concentration in plasma. In Davies DS, Prichard BNC, eds. *Biological Effects of Drugs in Relation to Their Plasma Concentration*. London and Basingstoke: Macmillan, 1973:227–238.)



Variability Liver Enzymes




Fig. 1. Bar graph (A and B) and pie chart (C) of weighted mean abundances of cytochrome P450 enzymes in livers from adult Caucasians. Error bars represent weighted standard deviation values. n , the number of livers.





FIGURE 5-3. Graphic representation of the different forms of human cytochrome-P450 enzyme (circles) with different but often overlapping substrate specificities. The arrows indicate the single metabolic pathways. Representative substrates are listed above each enzyme.

Fig. 2. A scatter plot of the measured abundance values of P450 (A and B) and UGT (C) enzymes. The number of samples is 24 for each enzyme except CYP2C9, CYP3A5, CYP3A7, CYP3A43, UGT1A3, UGT1A4, and UGT1A6 ($n = 23$). Lines indicate population means of the sets of data.

Pharmacogenomics




FIGURE 13-2. Strong genetic influence in the pharmacokinetics of nortriptyline is clearly demonstrated by the high correlation between the plasma concentration–time profile and the number of functional CYP2D6 genes possessed by an individual; the larger the number of functional genes, the higher is the clearance and the lower is the exposure profile following a single 25-mg dose of nortriptyline. (From: Dalén P, Dahl ML, Bernal Ruiz ML, et al. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. *Clin Pharmacol Ther* 1998;63:444–452.)




FIGURE 13-3. Plasma metoprolol concentrations after a single oral dose of 200-mg metoprolol tartrate were much higher in poor (colored line) than in extensive (black line) CYP2D6 metabolizers. Because metoprolol is a drug of high hepatic clearance, the difference between poor and extensive metabolizers is expressed in the large difference in oral bioavailability, because of differences in first-pass hepatic loss. (From: Lennard MS, Silas JH, Freestone S, et al. Oxidative phenotype—a major determinant of metoprolol metabolism and response. Reprinted by permission of New Eng J Med 1982;307:1558–1560.)





FIGURE 13-4. Genetics plays a significant role in the maintenance dose requirement of warfarin used in the treatment of various cardiovascular diseases. Shown are the unbound clearance of S-warfarin (black) in groups of patients with different CYP2C9 genotypes, all titrated and stabilized to a narrow target INR (International Normalization Ratio) range, a measure of anticoagulation, of between 2 and 3, and the mean weekly maintenance dose (obtained by summing the daily dose over 1 week, in color). Warfarin is administered as the racemate, with most of the therapeutic effect associated with the more active S-isomer, which is primarily eliminated by CYP2C9-catalyzed metabolism. Homozygous patients with two wild-type alleles (denoted by CYP2C9*1/*1) have the highest S-warfarin clearance and require the highest maintenance dose, and those with two of the most deficient alleles (CYP2C9*3/*3) have the lowest clearance and need the smallest maintenance dose. Heterozygous patients have intermediate clearance. However, as noted in Fig. 12-4 (Chapter 12, Variability), in addition to pharmacokinetic variability, there is also considerable interindividual variability in pharmacodynamics of this compound. (From: Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms of warfarin maintenance dose and metabolic clearance. *Clin Pharmacol Ther* 2002;72:702–710.)

Liver Function Tests



Liver Function Tests

Liver central organ of metabolism

- Metabolic homeostasis (glucose, amino acids, ...)
- Detoxification & clearance of most drugs

Liver specific clearance of substance



- Galactose elimination capacity (GEC)
- LiMAX Test (Methacetin)
- Caffeine clearance

Detection of product




- plasma, urine, breath

Non-invasive evaluation of liver function

- Transplantation & Hepatectomy
- Liver disease



LiMAX (metacethin)






Figure 2. Paracetamol clearance after oral and intravenous application of different doses. Depicted are the venous paracetamol concentrations in [mg/l] over time. Respective studies, doses and application route are stated in the title, number of subjects in the figure legend. All experimental data is depicted as mean \pm SD. Simulation curves are mean simulation curves, standard deviation of $\pm 10\%$ parameter changes (dark shaded area) and minimum and maximum of $\pm 10\%$ parameter changes (light shaded area). Details and references for experimental data is provided in Table 1.












Figure 5. Predicted time courses compared with model validation (bicarbonate kinetics in LiMAX tests and methacetin, paracetamol and DOB predictions. LiMAX simulations for healthy subjects (DOB and recoveries, also long term recoveries). Prediction of model validation based on independent LiMAX test data under different concentrations.







Sensitivity Analysis



Reduced liver function



Changes in Smoking & Cirrhosis



Caffeine PBPK




Caffeine & smoking



Caffeine (137X)

- world's most widely consumed psychoactive drug
- Metabolized in liver by **CYP1A2**
 - to **paraxanthine (17X)**, theobromine & theophylline
- Classical liver function test
 - Time course of caffeine
 - urinary ratios of methyl-xanthines
 - Caffeine/paraxanthine ratio
- Large Variability
 - Effects of lifestyle on expression
 - Smoking is one of such lifestyle factors






Denaro1996

- How is smoking affecting the clearance of caffeine ?

$$\text{Cup of coffee} + \text{Smoking} = ?$$

PKPD

- Kinetic model of caffeine liver metabolism
- Renal clearance
- Whole-body distribution kinetics




Denaro1996

Mean model



human (70kg, male),
mean microsomal CYP1A2 content,
non-smoker





CYP1A2

- CYP1A2 expression altered by many lifestyle factors
 - Strong effect: **Smoking**
- Altered function test results
 - clearance, half-life, kel, max value, metabolic ratios

Table 4. Parameter estimates of covariates obtained for logarithmic clearance values using the paraxanthine/caffeine ratio method (equation 1)

Covariate	Symbol used in equation 5	Estimate	95% Confidence interval		Mean resulting change of clearance (factor)
			Lower bound	Upper bound	
-	Intercept	0.264	-0.015	0.542	-
Coffee intake (litre day ⁻¹)	Slope _{coffee}	0.368	0.287	0.449	1.445
Body mass index (kg m ⁻²)	Slope _{BMI}	-0.010	-0.018	-0.002	0.990
Cigarettes/day					
Non-smokers	$V_{smoking\ habit\ index}$	0	-	-	Reference
1-5		0.195	0.065	0.324	1.215
6-10		0.383	0.253	0.509	1.467
11-20		0.504	0.386	0.621	1.655
>20		0.543	0.430	0.655	1.721
Oral contraceptives					
No	$V_{oral\ contraceptive\ index}$	0	-	-	Reference
Yes		-0.332	-0.236	-0.428	0.717
Country					
Germany	$V_{country\ of\ residence\ index}$	0	-	-	Reference
Bulgaria		-0.209	-0.356	-0.061	0.811
Slovakia		-0.303	-0.450	-0.156	0.739
Sex					
Male	$V_{sex\ index}$	0	-	-	Reference
Female		-0.111	-0.178	-0.044	0.895





CYP1A2 induction ▲

- Clearance ▲
- kel ▲
- T_{1/2} ▼
- T_{max} ▼
- px(17X)/caf(137X) ▲

Smoking


- CYP1A2 smoking effect
 - Distribution of liver microsome activity (log-normal) for non-smokers and smokers
 - Simulation of moderate smoking effect (6-10 cigarettes, ~40% increase)







The weighted means, coefficients of variation (CV), ranges, and heterogeneity analysis of the analyzed hepatic cytochrome P450 enzyme abundance data from 50 studies

Enzyme	Mean	CV (%)	Range*	No. of Livers	Q	I^2	Heterogeneity	Studies ^a
CYP1A2	39	78	1-263	148	19.54	54	Medium	[1-10]






CL: Clearance




k_{el} : elimination rate



$t_{1/2}$: half-life





px/caf ratio (4h, 6h)



Prediction: coffee consume

- Multiple dosing
- Adaption to smoking status, i.e. high smokers, via dose response curve (CYP1A2 ~ smoking)



Modeling Tools, Software, Workflows

git repositories

GitHub is a code hosting platform for version control and collaboration. It lets you and others work together on projects from anywhere.

- Version control
 - Diffs & Branches
- Collaborative editing
 - Pull requests
- Continuous integration
 - unit tests
 - Commit hooks
- Releases & snapshots (citable code)
- Issue tracker
- Work anywhere & offline



CODE



DATA




Fig 1. The structure of a GitHub-based project illustrating project structure and interactions with the community.

doi:10.1371/journal.pcbi.1004947.g001

Perez.Riverol2016

<https://github.com/matthiaskoenig/cy3sbml/>

<https://github.com/matthiaskoenig/cy3sbml/commit/986ebbdd5e77d403cf031ff0a5230de4d28fc284>

Reproducible Analyses

Dynamic report generation !



Jupyter notebooks

- Web application that allows to create and share documents that contain live code, equations, visualizations and explanatory text.
- Open source, interactive data science and scientific computing across over 40 programming languages.
- Complete analysis, examples, test cases
<http://tellurium.readthedocs.io/en/latest/notebooks.html#feedback-oscillations>
http://localhost:8888/notebooks/feedback_oscillations.ipynb


R: Knitr



- Elegant, flexible and fast dynamic report generation with R
- BDL example
<https://github.com/matthiaskoenig/bdl-analysis>

Feedback oscillations

Model oscillations via feedback



```
import tellurium as te

r = te.loada """
model feedback()
// Reactions:
J0: $X0 -> S1; (VM1 * (X0 - S1/Keq1))/(1 + X0 + S1 + S4^h);
J1: S1 -> S2; (10 * S1 - 2 * S2) / (1 + S1 + S2);
J2: S2 -> S3; (10 * S2 - 2 * S3) / (1 + S2 + S3);
J3: S3 -> S4; (10 * S3 - 2 * S4) / (1 + S3 + S4);
J4: S4 -> $X1; (V4 * S4) / (KS4 + S4);

// Species initializations:
S1 = 0; S2 = 0; S3 = 0;
S4 = 0; X0 = 10; X1 = 0;


// Variable initialization:
VM1 = 10; Keq1 = 10; h = 10; V4 = 2.5; KS4 = 0.5;
end"""

res = r.simulate(0, 40, 500)
r.plot()

import matplotlib.pyplot as plt
plt.plot(res["[S1]"], res["[S2]"], 'o-', color="black")
plt.xlabel("[S1]")
plt.ylabel("[S2]");
```

Standard Formats

- Encoding of information in standard formats where possible
 - Models in SBML (core, comp, fbc)
 - Simulations in SED-ML
 - Minimal Information for models and simulation (MIRIAM, MIASE)
- Annotations to ontologies
 - Knowledge integration
 - Documentation
- Reproducibility
 - Reproducibility of results (roadrunner, COPASI, JWS)
- Model quality
 - Passes library tests (e.g., module unit tests, ...)
- Visualization
 - Iterative model cycle



König, Rodriguez, and Dräger
cy3sbml: A Cytoscape app for SBML
2017, manuscript in preparation
<https://github.com/matthiaskoenig/cy3sbml>

```

// -- Begin Antimony block converted from MAPKcascade.xml
// Created by libAntimony v2.9.3
model *MAPKcascade()

...
// Reactions:
J0: MKKK_P => MKKK; J0_V1*MKKK/((1 + (MAPK_PP/J0_K1)^J0_n)*(J0_K1 + MKKK));
J1: MKKK_P => MKKK; J1_V2*MKKK_P/(J1_KK2 + MKKK_P);
J2: MKK => MKK_P; J2_k3*MKKK_P*MKK/(J2_KK3 + MKK);
J3: MKK_P => MKK_PP; J3_k4*MKKK_P*MKK_P/(J3_KK4 + MKK_P);
J4: MKK_PP => MKK_P; J4_V5*MKK_PP/(J4_KK5 + MKK_PP);
J5: MKK_P => MKK; J5_V6*MKK_P/(J5_KK6 + MKK_P);
J6: MAPK => MAPK_P; J6_k7*MKK_PP+MAPK/(J6_KK7 + MAPK);
J7: MAPK_P => MAPK_PP; J7_k8*MKK_PP+MAPK_P/(J7_KK8 + MAPK_P);
J8: MAPK_PP => MAPK_P; J8_V9*MAPK_PP/(J8_KK9 + MAPK_PP);
J9: MAPK_P => MAPK; J9_V10*MAPK_P/(J9_KK10 + MAPK_P);

...
end
// -- End Antimony block

// -- Begin PhraSEOML block converted from main.xml
// Created by libphrasedml v1.0.7
// Models
modell = model "MAPKcascade"

// Simulations
sim1 = simulate uniform(0, 4000, 1000)

// Tasks
task1 = run sim1 on modell


// Repeated Tasks
repeat1 = repeat task1 for modell.J1_KK2 in [1, 10, 40], reset=true

// Outputs
plot "Sampled Simulation" repeat1.time vs repeat1.MKK, repeat1.MKK_P, repeat1.MAPK_PP
// -- End PhraSEOML block

```



Sampled Simulation



Modeling Tools

- **libroadrunner:** High performance SBML simulator
- **tellurium:** Python based modeling environment (library & notebook)

Medley K, Choi K, **König M**; Smith L, Gu S, Joseph Hellerstein, Sealfon S., Sauro HM.
Tellurium Notebooks - An Environment for Dynamical Model Development, Reproducibility, and Reuse
[submitted, 2017]

Somogyi, Bouteiller, Glazier, **König**, Medley, Swat, Sauro.
libRoadRunner: a high performance SBML simulation and analysis library.
Bioinformatics. **2015**

Visualization & Data Integration

The screenshot shows the cy3sbml application interface. On the left, the 'Control Panel' displays a tree view of sessions and a table for 'Network', 'Nodes', and 'Edges'. The main area contains two diagrams: a detailed metabolic network with nodes like 'Vmax_v6', 'Km_C', and various reaction arrows, and a simplified schematic labeled 'Cell' showing metabolites A, B, and C in a cycle with import (bA), export (bB, bC), and reaction steps (v1-v4). The right panel is the 'Results Panel' for the 'Koenig_demo_10' model, providing a 'Description' of the demonstration model, terms of use, and copyright information. Below these panels is a 'Table Panel' showing a list of parameters with columns for shared name, name, id, sbml-type, SBO, metaid, biomodels.sbo, go, fma, label, value, units, derivedUnits, and constant.

shared name	name	id	sbml-type	SBO	metaid	biomodels.sbo	go	fma	label	value	units	derivedUnits	constant
external compartment	external c...	e	compartment	SBO:0000	meta_228897	SBO:000290	GO:0005	FMA:7022	external co...	1.0E-6	m3	m^-3	
cell compartment	cell comp...	c	compartment	SBO:0000	meta_780467	SBO:000290	GO:0005	FMA:68446	cell compar...	1.0E-6	m3	m^-3	
plasma membrane	plasma m...	m	compartment	SBO:0000	meta_302647	SBO:000290	GO:0005	FMA:63843	plasma me...	1.0	m2	m^-2	
metabolic scaling fa...	metabolic	scale_f	parameter	SBO:0000	meta_2131c9	SBO:000027	Km_C		metabolic s...	3.0	mM	molesm^-1l0	
Vmax_B0	Vmax_B0		parameter	SBO:0000	meta_371a28	SBO:000186			dimensionless	1.0E-6	dimensionless	dimensionless	
Vmax_B0	Vmax_B0		parameter	SBO:0000	meta_a3890f	SBO:000186			dimensionless	2.0	moles_per_s	moles^1l0	
Vmax_B0	Vmax_B0		parameter	SBO:0000	meta_351807	SBO:000186			dimensionless	2.0	moles_per_s	moles^1l0	
Vmax_v2	Vmax_v2		parameter	SBO:0000	meta_074658	SBO:000186			dimensionless	5.0	moles_per_s	moles^1l0	
Vmax_v3	Vmax_v3		parameter	SBO:0000	meta_142e99	SBO:000186			dimensionless	0.5	moles_per_s	moles^1l0	
Vmax_v5	Vmax_v5		parameter	SBO:0000	meta_70f637	SBO:000186			dimensionless	0.5	moles_per_s	moles^1l0	
Km_A	Km_A		parameter	SBO:0000	meta_30f0w1	SBO:000027	Km_A		dimensionless	1.0	moles_per_s	moles^1l0	
Vmax_v6	Vmax_v6		parameter	SBO:0000	meta_200451	SBO:000186	Vmax_v6		dimensionless	0.5	moles_per_s	moles^1l0	

König

cy3sabiork: A Cytoscape app for visualizing kinetic data from SABIO-RK

2016 [version 1; referees: 2 approved with reservations]

<http://f1000research.com/articles/5-1736/v1>

<https://github.com/matthiaskoenig/cy3sabiork>

König, Rodriguez, and Dräger

cy3sbml: A Cytoscape app for SBML


2017, manuscript in preparation

<https://github.com/matthiaskoenig/cy3sbml>

Open Positions

- **PhD Position** (ASAP, 3 years funding)
- **Google Summer of Code 2018** (Application End February, 2-3 month scholarship)

<https://livermetabolism.com>



König Lab

Systems Medicine of the Liver

The [König](#) group works on computational modeling, data science, bioinformatics methods and machine learning on biological, medical and clinical data. Main research interest is the predictive modeling of physiological processes and systems with focus on metabolic research in the liver.

Key projects are the personalized evaluation of liver function tests and multi-scale modeling of the liver. For more information have a look at our [publications](#) and [projects](#).

Dr. Matthias König

[More]

Junior Group Leader
LiSyM - Systems Medicine of the Liver
Institute for Biology, Institute for Theoretical Biology
Humboldt Universität zu Berlin
Invalidenstraße 43, 10117 Berlin, Germany
+49 30 2093-8450
koenigmx@hu-berlin.de



[matthiaskoenig](#)
[konigmatt](#)
[orcid](#)
[LinkedIn](#)
[ResearchGate](#)
[Google Scholar](#)
[Publons](#)



Our projects

[More]

Here you can find information about our latest projects. Most of them are hosted on GitHub and Open Source. Core interests are the computational modeling of liver metabolism and multi-scale modes of liver function.



Our publications

[More]

Scientific publications and preprints can be found below. We are trying to publish as much as possible of our scientific work as Open Access.



Open Positions

[More]

We are hiring PhD students! Bachelor and Master students, and research interns are always welcome. Just send a mail to [Matthias König](#).

Tutorial

- **Tutorial Data**

<https://github.com/matthiaskoenig/pkpd-tutorial>

<http://bit.ly/pkpd-tutorial>

- **Evaluation**

Wichtige Modelle der Quantitativen Biologie aus der Literatur.

<https://evaluation.hu-berlin.de/unizensus/evaluation/sl/hAj825L82Q0y>

Computerübungen Simulation von Mathematischen Modellen

<https://evaluation.hu-berlin.de/unizensus/evaluation/sl/WEPq09ZWWTzW9>

